760

TRANSGLUTAMINASE 2 IS ELEVATED IN CROHN’S DISEASE ASSOCIATED STRICTURES AND EXERTS PROFIBROTIC ACTIVITIES IN MYOFIBROBLASTS AND EXPERIMENTAL INTESTINAL FIBROSIS

Date
May 20, 2024
Explore related products in the following collection:

Background: Inflammatory bowel disease (IBD)-associated intestinal fibrosis is a significant clinical problem. Excessive accumulation of extracellular matrix (ECM) derived from intestinal myofibroblasts (HIMF) is a hallmark of intestinal strictures. Transglutaminase (TG)2 is involved in covalent cross-linking of ECM-associated proteins, increases ECM stiffness and has direct pro-fibrotic effects. We investigated the role of TG2 in intestinal fibrosis in human tissues, HIMF and transgenic mouse models.
Method: TG2 activity and expression in human tissues from Crohn’s disease (CD) strictures (CDs; n=10), CD non-strictured (CDns; n=20), ulcerative colitis (UC; n=10) and non-IBD controls (NL; n=14) were assessed by immunofluorescence (IF), qPCR, in-situ hybridization (ISH), and biotinylated cadaverin incorporation (BCI). Relative contribution of TG2 was measured by BCI using a TG2-selective blocking antibody (TAb). The cellular source of TG2 was evaluated by IF. HIMF ECM production was measured using a novel ECM deposition assay and TG2-specific inhibitors. HIMF were exposed to TAb or isotype control, and bulk RNA-sequencing (RNAseq) analysis was performed. Tamoxifen-inducible global Cre/TG2 floxed conditional KO (cKO) mice were generated and used in the DSS and TNBS fibrosis models.
Results: Total TG activity was increased in CDs and UC vs. NL in the submucosa (SM) and muscularis propria (MP; P≤ 0.04). Strikingly 90-99% of TG activity was attributable to TG2 in all groups. TG2 activity correlated with fibrosis scores (P≤0.02), but not inflammation scores. TG2 expression was elevated in CDs patients vs. NL in qPCR and ISH (P≤0.05). IF revealed HIMF as the major source of TG2 in the intestine as indicated by colocalization with alpha-SMA and vimentin. HIMF, invitro, produced active TG and 82–97% was attributable to TG2. Inhibition of TG2 using a cell-permeable inhibitor or TAb reduced fibronectin (FN) and collagen (COL)1 and 3 deposition by HIMF. RNAseq showed TAb-treated cells expressed 432 downregulated and 402 upregulated genes. Functional enrichment analysis showed pathways associated with fibroblast activation/proliferation, ECM, and fibrosis-associated signaling (e.g. AKT) pathways to be downregulated in TAb-treated HIMF. Associated genes included nuclear protein (NUPR1) and sphingolipid signaling pathway proteins (SMPD1 and CTSD), which may be potential targets for TG2-mediated activity in HIMF. Deletion of TGM2 prior to inducing murine DSS or TNBS experimental fibrosis did not lead to any difference in inflammation, but decreased fibrosis (picrosirius red intensity, COL1/FN expression, wall thickness) in TG2 cKO mice vs. wild type (P≤0.05).
Conclusions: TG2 is involved in inflammation-independent progression of intestinal fibrosis and may represent a future anti-fibrotic target.

Tracks

Related Products

Thumbnail for EXHALED BREATH ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IS ASSOCIATED WITH LUMINAL DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS
EXHALED BREATH ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IS ASSOCIATED WITH LUMINAL DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS
The evaluation of volatile organic compounds (VOCs) in exhaled breath shows promise as an entirely non-invasive strategy to evaluate for inflammation with high patient acceptance…
Thumbnail for THE BREATH METABOLOME SIGNATURE IS LINKED WITH DIAGNOSIS OF EOSINOPHILIC ESOPHAGITIS:
PILOT STUDY ASSESSING EXHALED VOLATILE ORGANIC COMPOUNDS
THE BREATH METABOLOME SIGNATURE IS LINKED WITH DIAGNOSIS OF EOSINOPHILIC ESOPHAGITIS: PILOT STUDY ASSESSING EXHALED VOLATILE ORGANIC COMPOUNDS
Eosinophilic esophagitis (EoE) is a chronic immune mediated esophageal condition leading to dysphagia, strictures, and food impactions. Endoscopic biopsies remain the gold standard for diagnosis…
Thumbnail for DUAL ACTIVATION OF GCGR/GLP1R SIGNALING AMELIORATES INTESTINAL FIBROSIS VIA METABOLIC REGULATION OF HISTONE H3K9 LACTYLATION IN EPITHELIAL CELLS
DUAL ACTIVATION OF GCGR/GLP1R SIGNALING AMELIORATES INTESTINAL FIBROSIS VIA METABOLIC REGULATION OF HISTONE H3K9 LACTYLATION IN EPITHELIAL CELLS
Intestinal fibrosis is a significant clinical challenge in inflammatory bowel diseases, but no effective anti-fibrotic therapy is currently available. GCGR and GLP1R are both peptide hormone receptors involved in energy metabolism of epithelial cells…